Aim To investigate whether chronic statin treatment after coronary artery bypass grafting (CABG) protects patients from major cardiac events and provides percutaneous coronary intervention (PCI) free survival. Methods A total of 232 patients with previous CABG and chronic statin therapy were selected retrospectively and were divided into two groups according to a dosage of atorvastatin per day, e. g., 20 mg or 40 mg. Groups were compared for the major cardiac events and freedom from PCI by Kaplan Meier analysis as the primary end point. Patency of grafts including left internal thoracic artery (LITA) and saphenous vein (SVG) and progression of non-grafted native vessel disease were also evaluated as secondary end points. Results Cardiac mortality, periprocedural myocardial infarction (MI), target vessel revascularization and percutaneous coronary intervention free survival were as follows: 2.9% versus 2.1% (p=1.000); 16.1% versus 21.1% (p=0.331); 56.93% versus 52.63% (p>0.005); 58.4% versus 63.2% (log-rank test; p= 0.347) in atorvastatin 20 mg and atorvastatin 40 mg groups, respectively. However, these results were not statistically significant between two groups (p>0.005). Patency of openness of grafts including LITA and SVG and progression of non-grafted native vessel disease were similar between groups (p=0.112, p=0.779, p=0.379 and p=0.663, respectively). Conclusion Low-dose long-term statin treatment had similar outcomes on major cardiac events and identical rate of freedom from percutaneous coronary intervention after coronary artery bypass grafting compared with high-dose long-term statin treatment. It is better to start from low dose statin treatment after surgical interventions.
Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Sciascio D, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004. p. 674–8.
2.
Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G. Atorvastatin pretreatment improves outcomes in patients with acute coronary.
3.
Fitzgibbon G, Kafka H, Leach A, Keon W, Hooper G, Burton J. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996. p. 616–26.
4.
Motwani J, Topol E. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998. p. 916–31.
5.
Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective metaanalysis of data from 90.056 participants in 14 randomized trials of statins. Lancet. 2005. p. 1267–78.
6.
Eagle K, Guyton R, Davidoff R, Ewy G, Fonger J, Gardner T, et al. AHA Guidelines for Coronary Artery Bypass Graft Surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. American College of Cardiology/American Heart Association; 1999. p. 1262–347.
7.
Reiber J, Van Der Zwet P, Land V, C. Advances in Quantitative Coronary Arteriography. Kluwer Academic Publishers; 1993. p. 75–111.
8.
Canner P, Thompson B, Knatterud G, Geller N, Campeau L, Zucker D. An application of the Zucker-Wittes modified ratio estimate statistic in the POST CABG Clinical Trial. Control Clin Trials. 1997. p. 318–27.
9.
Campeau L, Knatterud G. Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis.
10.
London U. Kluwer Academic Publishers; 1996. p. 203–13.
11.
Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996. p. 1001–9.
12.
Anonymus. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998. p. 1349–57.
13.
Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, Birgelen V, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation. 2002. p. 2180–3.
14.
Chan A, Bhatt D, Chew D, Quinn M. Moliterno DJ, Topol EJ, Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002. p. 691–6.
15.
Chan A, Bhatt D, Chew D, Quinn M, Moliterno D, Topol E. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003. p. 1750–6.
16.
Patti G, Cannon C, Murphy S, Mega S, Pasceri V, Briguori C. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011. p. 1622–32.
17.
Carrier M, Cossette M, Pellerin M, Hébert Y, Bouchard D, Cartier R. Statin treatment equalizes longterm survival between patients with single and bilateral internal thoracic artery grafts. Ann Thorac Surg. 2009. p. 789–95.
18.
Smith Sc A, Blair S, Bonow R, Brass L, Fonarow G. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006. p. 2363–72.
19.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001. p. 2486–97.
20.
Grundy S, Cleeman J, Merz C, Brewer H, Jr, Clark L, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004. p. 227–39.
21.
Campeau L, Enjalbert M, Lespérance J, Bourassa M, Kwiterovich P, Jr, et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984. p. 1329–32.
22.
Fitzgibbon G, Kafka H, Leach A, Keon W, Hooper G, Burton J. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996. p. 616–26.
23.
Cashin-Hemphill L, Mack W, Pogoda J, Sanmarco M, Azen S, Blankenhorn D. Beneficial effects of colestipolniacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990. p. 3013–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
